|
| PUBLICATIONS (Ranked by Impact Factor of the Journal) |
LABORATORY RESEARCH
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
Researchers show that the NAD+-dependent deacetylase SIRT1 is overexpressed in human chronic myelogenous leukemia (CML) stem cells. [Cancer Cell] Abstract | Press Release
N-Cadherin in Osteolineage Cells Is Not Required for Maintenance of Hematopoietic Stem Cells
There is evidence suggesting that N-cadherin expression on osteoblast lineage cells regulates hematopoietic stem cell function and quiescence. To test this hypothesis, scientists conditionally deleted N-cadherin (Cdh2) in osteoblasts using Cdh2flox/flox Osx-Cre mice. [Blood] Abstract
F Box Protein FBXL2 Targets Cyclin D2 for Ubiquitination and Degradation to Inhibit Leukemic Cell Proliferation
Investigators describe the behavior of a relatively new SCF (Skip-Cullin1-F-box protein) subunit, termed FBXL2, that ubiquitinates and destabilizes cyclin D2 protein leading to G0 phase arrest and apoptosis in leukemic and B lymphoblastoid cell lines. [Blood] Abstract
Knock-In of a FLT3/ITD Mutation Cooperates with a NUP98-HOXD13 Fusion to Generate Acute Myeloid Leukemia in a Mouse Model
Previous work has shown that insertion of a FLT3/ internal tandem duplication (ITD) mutation into the murine Flt3 gene induces a myeloproliferative neoplasm, but not progression to acute leukemia, suggesting that additional cooperating events are required. Scientists combined the FLT3/ITD mutation with a model of myelodysplastic syndrome involving transgenic expression of the Nup98-HoxD13 fusion gene. [Blood] Abstract
Molecular and Cellular Effects of Oncogene Cooperation in a Genetically Accurate AML Mouse Model
Investigators have generated an acute myeloid leukemia (AML) mouse model using knock-in mouse strains to study cooperation of internal tandem duplication mutation in the Flt3 gene with commonly observed C/EBPα mutations. [Leukemia] Abstract
Overexpression of Wild-Type or Mutants Forms of CEBPA Alter Normal Human Hematopoiesis
Data underline the critical role of C/EBPα (CEBPA) in human hematopoiesis and demonstrate that C/EBPα mutations (alone or in combination) are insufficient to convert normal human hematopoietic stem/progenitors into leukemic initiating cells, although individually each altered normal hematopoiesis. [Leukemia] Abstract
Dynamic Interaction Between TAL1 Oncoprotein and LSD1 Regulates TAL1 Function in Hematopoiesis and Leukemogenesis
Here, scientists reported that protein kinase A-mediated phosphorylation regulates TAL1 interaction with the lysine-specific demethylase (LSD1) that removes methyl group from methylated Lys 4 on histone H3 tails. [Oncogene] Abstract
CLINICAL RESEARCH
Early Matched Sibling Hematopoietic-Cell Transplantation for Adult AML in First Remission Using an Age-Adapted Strategy: Long-Term Results of a Prospective GOELAMS Study
The GOELAMS LAM2001 phase III trial, involving 832 patients with acute myeloid leukemia (AML) (median: 46 years, range: 17-60) proposed HLA-identical sibling allograft of hematopoietic stem cells for all patients with an identified donor. [Blood] Abstract
Outcomes After Matched Unrelated Donor vs. Identical Sibling Hematopoietic Cell Transplantation (HCT) in Adults with Acute Myelogenous Leukemia (AML)
Researchers analyzed outcomes of 2,223 adult AML patients who underwent allogeneic HCT between 2002 and 2006 (matched related donor, n=624; 8/8 human leukocyte antigen locus matched unrelated donor (MUD), n=1193; 7/8 MUD, n=406). [Blood] Abstract
 |
|
| INDUSTRY NEWS |
Coronado Biosciences Announces IND Submission for CNDO-109 for the Treatment of Relapsed Acute Myeloid Leukemia
Coronado Biosciences, Inc. announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for CNDO-109, a novel biologic that primes natural killer cells without the need for cytokines (IL-2), and is being studied for the treatment of patients with high risk acute myeloid leukemia in first complete remission. [Coronado Biosciences, Inc.] Press Release
Formula Pharmaceuticals Appoints Dr. Wolfgang Oster as Chairman, Board of Directors
Formula Pharmaceuticals announced the appointment of Wolfgang Oster, MD PhD as Chairman of the Board of Directors. [Formula Pharmaceuticals, Inc.] Press Release
Ambit Biosciences Appoints Athena Countouriotis as Chief Medical Officer
Ambit Biosciences announced the appointment of Athena Countouriotis, M.D., as chief medical officer. [Ambit Biosciences, Inc.] Press Release
Seattle Genetics Reports Fourth Quarter and Year 2011 Financial Results
Seattle Genetics, Inc. reported financial results for the fourth quarter and year ended December 31, 2011. The company also highlighted the ADCETRIS (brentuximab vedotin) product launch, recent ADCETRIS clinical data, ongoing and planned clinical development activities and upcoming milestones. [Seattle Genetics, Inc.] Press Release
Research Partnership to Improve Treatments for Cancer Patients
The Australian Cancer Research Foundation has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute. [Walter and Eliza Hall Institute] Press Release |
|
|
|
